US20090312359A1 - Use of methylnaltrexone and related compounds for treatment of gastrointestinal dysfunction induced by endogenous opioids - Google Patents
Use of methylnaltrexone and related compounds for treatment of gastrointestinal dysfunction induced by endogenous opioids Download PDFInfo
- Publication number
- US20090312359A1 US20090312359A1 US12/333,912 US33391208A US2009312359A1 US 20090312359 A1 US20090312359 A1 US 20090312359A1 US 33391208 A US33391208 A US 33391208A US 2009312359 A1 US2009312359 A1 US 2009312359A1
- Authority
- US
- United States
- Prior art keywords
- methylnaltrexone
- administration
- opioid
- induced
- opioids
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
- 0 *[N+]1(C)CCC23C4=C5C=CC(O)=C4OC2C(=O)CCC3(O)C1C5 Chemical compound *[N+]1(C)CCC23C4=C5C=CC(O)=C4OC2C(=O)CCC3(O)C1C5 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/485—Morphinan derivatives, e.g. morphine, codeine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
Definitions
- the present invention is directed at the treatment of certain side effects associated with the use of opioids as analgesics.
- the present invention is directed at treating opioid-induced dysphoria, opioid-induced pruritus, opioid-induced urinary retention, inhibition of gastric emptying, and decreased gut motility.
- Opioids are effective analgesics, however, their use is associated with a number of undesirable side effects.
- One of these side effects is pruritus, or itching.
- Pruritus is a common side effect associated with the use of opioids and may be very severe. Pruritus can occur when the opioid is administered intramuscularly, intravenously, transdermally, transmucosally or intrathecally.
- opioid induced pruritus results from the release of histamine in response to the administration of opioids.
- Opioids are thought to stimulate histamine release by binding to opioid receptors on the central nervous system. This, in turn, causes peripheral nerves and histamine containing cells to release histamine.
- antihistamines have a variable effect on opioid induced pruritus. Additionally, the use of antihistamines, when effective, only treats the symptom after it has occurred, rather than preventing its occurrence.
- urinary retention Another undesirable side effect of opioids is urinary retention, or the patient's inability to spontaneously empty his or her bladder.
- This urinary retention is a common side effect that can occur when opioids or related compounds are administered intramuscularly, intravenously, transmucosally, transdermally, or intrathecally. It is not clear why opioids cause urinary retention, but it is thought to be related to the central anticholinergic stimulation that opioids induce. Based on this theory, a number of cholinergic-type drugs have been used to treat urinary retention. However, due to the side effects of cholinergic drugs, catheterization of the bladder with a tube to drain urine remains the mainstay of treatment.
- Another opioid-induced side effect is dysphoria, a feeling of unpleasantness or discomfort. Many subjects, especially those without pain, report unpleasant psychomimetic responses to the administration of an opioid alone. These responses have been previously attributed to activation of centrally located opioid receptors.
- This opioid-induced dysphoria is commonly treated by the addition of other drugs, such as benzodiazepines, to decrease the dysphoria or to blunt the recall of the dysphoria. These drugs, however are associated with increased levels of sedation and may enhance respiratory depression caused by the opioid.
- opioid antagonists which cross the blood-brain-barrier, or which are administered directly into the central nervous system.
- Opioid antagonists such as naltrexone and naloxone have been administered intramuscularly or orally to treat opioid induced pruritus.
- Naltrexone and naloxone are highly lipid soluble and rapidly diffuse across biological membranes, including the blood-brain-barrier.
- naltrexone, naloxone and other opioid antagonists also reduce the analgesic effect of the opioid being used.
- quaternary amine opioid antagonist derivatives such as methylnaltrexone, do not reduce the analgesic effect of the opioids.
- These quaternary amine opioid antagonist derivatives which have a relatively higher polarity and reduced lipid solubility when compared to the tertiary forms of the drugs, were specifically developed to not traverse the blood-brain-barrier or to traverse it at a greatly reduced rate. Since these quaternary opioid antagonist derivatives do not cross the blood-brain-barrier, peripheral administration of these antagonists would not be expected to be effective in the treatment of an opioid induced side effect caused by the opioid within the central nervous system.
- oral medications are particularly desirable both for the treatment of opioid-induced side effects (such as urinary retention, pruritus, and some forms of constipation) and for the treatment of nonopioid-induced side effects (such as other forms of constipation and delayed gastric emptying from enteric feeding).
- opioid-induced side effects such as urinary retention, pruritus, and some forms of constipation
- nonopioid-induced side effects such as other forms of constipation and delayed gastric emptying from enteric feeding.
- the present invention is directed at methods for preventing and treating endogenous opioid induced gastrointestinal dysfunction.
- the method for preventing endogenous opioid-induced dysfunction comprises administering methylnaltrexone or other quaternary derivatives of noroxymorphone to a patient, wherein the route of administration is selected from the group consisting of parenteral, intramuscular, intravenous and oral administration, in a standard or enterically coated preparation in an effective amount, more preferably in an amount between 0.03 and 1.0 mg/kg.
- the present invention is directed at methods for preventing and treating opioid-induced dysphoria, opioid-induced pruritus, opioid-induced urinary retention, opioid- or nonopioid-induced inhibition of gastric emptying by enteric feeding, and opioid- or nonopioid-induced constipation.
- opioid-induced dysphoria opioid-induced pruritus
- opioid-induced urinary retention opioid- or nonopioid-induced inhibition of gastric emptying by enteric feeding
- opioid- or nonopioid-induced constipation When used as a treatment for these opioid- and nonopioid-induced side effects, orally administered, particularly if enteric coated, methylnaltrexone (MNTX) or other quaternary derivatives of noroxymorphone (QDMN) provides prolonged relief of the side effects.
- MNTX methylnaltrexone
- QDMN quaternary derivatives of noroxymorphone
- enteric coating surprisingly allows for equal or better efficacy despite lower plasma levels.
- Idiopathic constipation i.e., that due to causes other than exogenous administration of opioids, may be mediated by opioid sensitive mechanisms.
- Endogenous opioid receptors have been identified in the gut, and these receptors may modulate gut motility.
- R is allyl or a related radical such as chlorallyl, cyclopropyl-methyl or propargyl
- X is the anion of an acid, especially a chloride, bromide, iodide or methylsulfate anion.
- the presently preferred quaternary derivative of noroxymorphone is methylnaltrexone.
- Methylnaltrexone is a quaternary amine derivative of naltrexone.
- Methylnaltrexone has been found to have only 2 to 4% of the opiate antagonistic activity of naltrexone in vivo due to its inability to pass the blood-brain-barrier and bind to the opiate receptors in the central nervous system.
- Opioids are typically administered at a morphine equivalent dosage of: 0.005 to 0.15 mg/kg body weight for intrathecal administration; 0.05 to 1.0 mg/kg body weight for intravenous administration; 0.05 to 1.0 mg/kg body weight for intramuscular administration; 0.05 to 1.0 mg/kg body weight/hour for transmucosal or transdermal administration.
- morphine equivalent dosage is meant representative doses of other opioids which equal one milligram of morphine, for example 10 mg meperidine, 1 mg methadone, and 80 ⁇ g fentanyl.
- methylnaltrexone is administered at a dosage of: 0.03 to 1.0 mg/kg body weight for intravenous administration; 0.03 to 1.0 mg/kg body weight for intramuscular administration; 0.03 to 1.0 mg/kg body weight for transmucosal administration and 1.0 to 40.0 mg/kg body weight for oral administration.
- enteric coated methylnaltrexone is administered at a dosage of 1.0 to 80.0 mg/kg body weight for oral administration.
- the administration of the methylnaltrexone is preferably commenced prior to administration of the opioid to prevent opioid-induced dysphoria, pruritus, urinary retention, inhibition of gastric emptying with enteric feeding, or constipation. It is desirable to commence administration of methylnaltrexone about 5 minutes for parenteral MNTX administration and 20 minutes for enteral MNTX administration prior to administration of opioids in order to prevent these opioid-induced side effects. It is also preferable to administer the methylnaltrexone prior to the onset of nonopioid-induced gastric dysfunction symptoms, inhibition of gastric emptying with enteric feeding or constipation, in order to prevent these symptoms from manifesting. While the prevention of symptoms is preferred, methylnaltrexone administration may also be commenced after the administration of the opioid or after the onset of opioid induced symptoms as a treatment for those symptoms.
- Methylnaltrexone is rapidly absorbed after oral administration from the stomach and bowel. Initial plasma levels of the drug are seen within 5-10 minutes of the administration of non-enteric coated compound. Addition of an enteric coating which prevents gastric absorption is associated with lower plasma levels of the methylnaltrexone. Surprisingly, the addition of an enteric coating (i.e., a coating which will prevent degradation or release in the stomach, but will release drug in the small and large bowel) appears to enhance the efficacy of methylnaltrexone in the prevention of decreases in gut motility by intravenously administered opioids (morphine).
- an enteric coating i.e., a coating which will prevent degradation or release in the stomach, but will release drug in the small and large bowel
- methylnaltrexone is formulated with saline or other physiologically acceptable carriers; for intramuscular administration, the methylnaltrexone is formulated with saline or other pharmacologically acceptable carriers; for transmucosal administration the methylnaltrexone is formulated with a sugar and cellulose mix or other pharmacologically acceptable carriers known in the art; and for oral administration, the methylnaltrexone is formulated with pharmacologically acceptable binders to make a tablet or capsule with or without an enteric coating. Methods for such formulations are well known to those skilled in the art.
- the MNTX is enterically coated and administered orally.
- the enteric coating may be made of any suitable composition. Suitable enteric coatings are described, for example, in U.S. Pat. Nos. 4,311,833 to Namikoshi, et al.; 4,377,568 to Chopra; 4,385,078 to Onda, et al.; 4,457,907 to Porter; 4,462,839 to McGinley, et al.; 4,518,433 to McGinley, et al.; 4,556,552 to Porter, et al.; 4,606,909 to Bechgaard et al.; 4,615,885 to Nakagame, et al.; 4,670,287 to Tsuji; 5,536,507 TO Abramowitz, et al.; 5,567,423 to Ying, et al.; 5,591,433 to Michael, et al.; 5,597,564 to Ying, et al.; 5,609,871 to Michael,
- enteric coating compositions include alkyl and hydroxyalkyl celluloses and their aliphatic esters, e.g., methylcellulose, ethylcellulose, hydroxyethylcellulose, hydroxypropylcellulose, hydroxybutylcellulose, hydroxyethylethylcellulose, hydroxyprophymethylcellulose, hydroxybutylmethylcellulose, hydroxypropylcellulose phthalate, hydroxypropylmethylcellulose phthalate and hydroxypropylmethylcellulose acetate succyere; carboxyalkylcelluloses and their salts, e.g., carboxymethylethylcellulose; cellulose acetate phthalate; cellulose acetate trimellitate, polycarboxymethylene and its salts and derivatives; polyvinylalcohol and its esters: polyvinyl acetate phthalate; polycarboxymethylene copolymer with sodium formaldehyde carboxylate; acrylic polymers and copolymers, e.g., methacrylic acid-methyl me
- enteric coatings include polyvinylacetate esters, e.g., polyvinyl acetate phthalate; alkyleneglycolether esters of copolymers such as partial ethylene glycol monomethylether ester of ethylacrylate-maleic anhydride copolymer or diethyleneglycol monomethylether ester of methylacrylate-maleic anhydride copolymer, N-butylacrylate-maleic anhydride copolymer, isobutylacrylate-maleic anhydride copolymer or ethylacrylate-maleic anhydride copolymer; and polypeptides resistant to degradation in the gastric environment, e.g., polyarginine and polylysine.
- the presently preferred enteric coating comprises cellulose acetate phthalate.
- the enteric coating material may be mixed with various excipients including plasticizers such as triethyl citrate, acetyl triethyl citrate, diethyl phthalate, dibutyl phthalate, dibutyl subacute, dibutyl tartrate, dibutyl maleate, dibutyl succinate and diethyl succinate and inert fillers such as chalk or pigments.
- plasticizers such as triethyl citrate, acetyl triethyl citrate, diethyl phthalate, dibutyl phthalate, dibutyl subacute, dibutyl tartrate, dibutyl maleate, dibutyl succinate and diethyl succinate and inert fillers such as chalk or pigments.
- composition and thickness of the enteric coating may be selected to dissolve immediately upon coated with the digestive juice of the intestine.
- the composition and thickness of the anterior coating may be selected to be a time-release coating which dissolves over a selected period of time, as is well known in the art.
- the amount of enteric coating depends on the particular enteric coating composition used and is preferably sufficient to substantially prevent the absorption of MNTX in the stomach.
- Hydroxyalkyl celluloses and their aliphatic esters, carboxyalkyl celluloses and their salts, polycarboxymethylene and its salts and derivatives, polyvinyl alcohol and its esters, polycarboxymethylene copolymer with sodium formaldehyde carboxylates, polyvinylpyrrolidone, and polyethylene glycol and its esters can be applied as enteric coatings by first dissolving the compound in a minimum amount of water. Alcohol is then added to the point of incipient cloudiness. The mixture can then be applied by conventional techniques.
- cellulose acetate phthalate may be accomplished by simply dissolving the cellulose acetate phthalate in a minimum amount of alcohol and then applying by conventional techniques.
- Hydrogenated vegetable oils may be applied by first dissolving the oil in a minimal amount of a non-polymer solvent, such as methylene chloride, chloroform or carbon tetrachloride, then adding alcohol to the point of incipient cloudiness and then applying by conventional techniques.
- the MNTX is coated with Eudragit L100 or S100, a methacrylic acid copolymer enteric coating, at a 50% coating level to provide stability at gastric pH and dissolution at gut pH per a US Pharmacopeia (USP) standard for enteric coatings.
- USP US Pharmacopeia
- transdermal administration is preferably via a patch applied to the skin with a membrane of sufficient permeability to allow diffusion of MNTX at a fixed rate in the range of 1.0 to 10.0 mg/hr.
- the rate of administration may be varied by varying the size of the membrane contact area and/or applying an electrical wiring potential to a drug reservoir.
- the patch preferably holds 25 mg to 1 gram of available drug in the reservoir plus additional drug as needed for the mechanics of the system.
- methylnaltrexone is used as an example of a particularly effective QDNM. It is apparent that other QDNM's may be used as desired.
- the following Examples are intended to illustrate aspects of the invention and are not to be construed as limitations upon it.
- the methylnaltrexone used in the following Examples was manufactured by Mallinckrodt Pharmaceuticals, St. Louis, Mo.
- the Enteric Coating was manufactured by Coating Place, Inc., Verona, Wis.
- methylnaltrexone at a dosage of 0.3 mg/kg of body weight was administered intravenously as a saline solution containing methylnaltrexone in a concentration of 5 mg/ml to each of the patients. Eighty percent of the 10 patients exhibited relief from the pruritus sixty minutes after receiving methylnaltrexone.
- a control group 8 patients were treated with morphine sulfate administered directly to the central nervous system or intravenously.
- the morphine sulfate was administered at 0.1 mg/kg body weight.
- the patients in the study had been treated for pain resulting from surgery. All the patients exhibited pruritus as a side effect of the morphine sulfate administration.
- Morphine (0.05) mg/kg intravenous) was administered to three volunteers after the oral administration of placebo, methylnaltrexone (6.4 mg/kg) in a gelatin capsule (which dissolves readily in the stomach), or methylnaltrexone after enteric coating (12.8 mg/kg of substance to yield a mass of 6.4 mg/kg methylnaltrexone incorporated) which has decreased release and absorption in the stomach.
- Oral-cecal transit time was measured using the lactulose-hydrogen breath test. Plasma levels of methylnaltrexone were measured and after the enteric coated preparation were lower.
- Two patients receiving morphine (375 mg/day and 18 mg/day) and receiving enteric tube feedings of 200 ml every four (4) hours were studied.
- the first patient had residual stomach contents of 50 cc to 100 cc, or 22.0-58.8% of administered feedings measured every 4 hours during a 24 hour control period. Prior to drug administration the residual volume had increased to 260 cc or >100% of previous feeding volume.
- the residual was 150 cc or 58% of the previous bolus feed, after the 3rd dose (12 hours) the residual was 75 cc or 30% of the previous feed, after the 5th dose (20 hours) the residual was 22 cc or 13% of the previous feed and after the 6th and final dose (24 hours) the residual was 8 cc or 5.5% of previous feed.
- the follow-up residual sampling after the final drug-tube feed interval had increased to 50 cc or 38% or previous feed.
- the second patient had greater than 200 cc residual or 100% of previous feedings on two consecutive samplings, that is 8 hrs and 4 hrs before drug administration.
- the first residual (4 hrs) was 0 cc
- the second residual (8 hrs) was 24 cc or 15% of previous bolus feed.
- Methylnaltrexone 0.45 mg/kg intravenously or a placebo.
- Those treated with Methylnaltrexone have resolution of their symptoms, while those administered placebo go on to require additional therapy (usually urinary catheterization).
Abstract
A method of for preventing or treating gastrointestinal dysfunction and constipation caused by endogenous opioids in a patient who has been chronically taking opioids. The method comprises administering methylnaltrexone or another quaternary derivative of noroxymorphone most preferably by parenteral, intramuscular, intravenous or oral route.
Description
- This application is a continuation of application Ser. No. 10/779,129, filed Feb. 12, 2004, now pending; which is a continuation of application Ser. No. 10/278,630, filed Oct. 23, 2002, abandoned; which is a divisional of application Ser. No. 09/862,169, filed May 21, 2001, now U.S. Pat. No. 6,608,075; which is a continuation of application Ser. No. 09/120,703, filed Jul. 22, 1998, now U.S. Pat. No. 6,274,591; which is a continuation-in-part of application Ser. No. 08/962,742, filed Nov. 3, 1997, now U.S. Pat. No. 5,972,954, the entire contents of each of which are herein incorporated by reference.
- This invention was made with government support under M01 RR00055 awarded by the National Institute of Health. The government has certain rights in the invention.
- The present invention is directed at the treatment of certain side effects associated with the use of opioids as analgesics. In particular the present invention is directed at treating opioid-induced dysphoria, opioid-induced pruritus, opioid-induced urinary retention, inhibition of gastric emptying, and decreased gut motility.
- Opioids are effective analgesics, however, their use is associated with a number of undesirable side effects. One of these side effects is pruritus, or itching. Pruritus is a common side effect associated with the use of opioids and may be very severe. Pruritus can occur when the opioid is administered intramuscularly, intravenously, transdermally, transmucosally or intrathecally.
- It is believed that the opioid induced pruritus results from the release of histamine in response to the administration of opioids. Opioids are thought to stimulate histamine release by binding to opioid receptors on the central nervous system. This, in turn, causes peripheral nerves and histamine containing cells to release histamine.
- Based on this theory a number of treatments have been used to alleviate opioid induced pruritus. The first is the use of antihistamines. However, antihistamines have a variable effect on opioid induced pruritus. Additionally, the use of antihistamines, when effective, only treats the symptom after it has occurred, rather than preventing its occurrence.
- Another undesirable side effect of opioids is urinary retention, or the patient's inability to spontaneously empty his or her bladder. This urinary retention is a common side effect that can occur when opioids or related compounds are administered intramuscularly, intravenously, transmucosally, transdermally, or intrathecally. It is not clear why opioids cause urinary retention, but it is thought to be related to the central anticholinergic stimulation that opioids induce. Based on this theory, a number of cholinergic-type drugs have been used to treat urinary retention. However, due to the side effects of cholinergic drugs, catheterization of the bladder with a tube to drain urine remains the mainstay of treatment.
- Another opioid-induced side effect is dysphoria, a feeling of unpleasantness or discomfort. Many subjects, especially those without pain, report unpleasant psychomimetic responses to the administration of an opioid alone. These responses have been previously attributed to activation of centrally located opioid receptors. This opioid-induced dysphoria is commonly treated by the addition of other drugs, such as benzodiazepines, to decrease the dysphoria or to blunt the recall of the dysphoria. These drugs, however are associated with increased levels of sedation and may enhance respiratory depression caused by the opioid.
- One treatment for side effects such as pruritis, urinary retention and dysphoria is the use of opioid antagonists which cross the blood-brain-barrier, or which are administered directly into the central nervous system. Opioid antagonists such as naltrexone and naloxone have been administered intramuscularly or orally to treat opioid induced pruritus. Naltrexone and naloxone are highly lipid soluble and rapidly diffuse across biological membranes, including the blood-brain-barrier. However, naltrexone, naloxone and other opioid antagonists also reduce the analgesic effect of the opioid being used.
- Many quaternary amine opioid antagonist derivatives, such as methylnaltrexone, do not reduce the analgesic effect of the opioids. These quaternary amine opioid antagonist derivatives, which have a relatively higher polarity and reduced lipid solubility when compared to the tertiary forms of the drugs, were specifically developed to not traverse the blood-brain-barrier or to traverse it at a greatly reduced rate. Since these quaternary opioid antagonist derivatives do not cross the blood-brain-barrier, peripheral administration of these antagonists would not be expected to be effective in the treatment of an opioid induced side effect caused by the opioid within the central nervous system. In fact, experiments show that to be effective in blocking the opioid receptors in the central nervous system, these antagonists must be injected directly into the central nervous system. However, injection of drugs directly into the central nervous system is undesirable since it increases the possibility of introducing bacterial or viral contamination to the central nervous system.
- It is desirable in the treatment of many conditions to have oral medications with prolonged effects. Such oral medications are particularly desirable both for the treatment of opioid-induced side effects (such as urinary retention, pruritus, and some forms of constipation) and for the treatment of nonopioid-induced side effects (such as other forms of constipation and delayed gastric emptying from enteric feeding).
- It is further desirable to develop a method for the prevention of opioid induced dysphoria, opioid induced pruritus, urinary retention, opioid- or nonopioid-induced delayed gastric emptying from enteric feeding, and constipation, which does not counteract the analgesic effects of the opioid, or risk increased levels of pain.
- The present invention is directed at methods for preventing and treating endogenous opioid induced gastrointestinal dysfunction.
- The method for preventing endogenous opioid-induced dysfunction, including gastric dysfunction and constipation, comprises administering methylnaltrexone or other quaternary derivatives of noroxymorphone to a patient, wherein the route of administration is selected from the group consisting of parenteral, intramuscular, intravenous and oral administration, in a standard or enterically coated preparation in an effective amount, more preferably in an amount between 0.03 and 1.0 mg/kg.
- The present invention is directed at methods for preventing and treating opioid-induced dysphoria, opioid-induced pruritus, opioid-induced urinary retention, opioid- or nonopioid-induced inhibition of gastric emptying by enteric feeding, and opioid- or nonopioid-induced constipation. When used as a treatment for these opioid- and nonopioid-induced side effects, orally administered, particularly if enteric coated, methylnaltrexone (MNTX) or other quaternary derivatives of noroxymorphone (QDMN) provides prolonged relief of the side effects. Furthermore, for treatment or prevention of delayed gastric emptying from enteric feeding and constipation, whether caused by extrinsic or endogenous opioids, enteric coating surprisingly allows for equal or better efficacy despite lower plasma levels. Idiopathic constipation, i.e., that due to causes other than exogenous administration of opioids, may be mediated by opioid sensitive mechanisms. Endogenous opioid receptors have been identified in the gut, and these receptors may modulate gut motility. Thus, administration of an opioid antagonist with peripheral action, such a methylnaltrexone or other quaternary derivatives of noroxymorphone, would block the effects of endogenous opioids.
- Quaternary derivatives of noroxymorphone are described in full in Goldberg et al., (supra), and in general are represented by the formula:
- wherein R is allyl or a related radical such as chlorallyl, cyclopropyl-methyl or propargyl, and X is the anion of an acid, especially a chloride, bromide, iodide or methylsulfate anion.
- The presently preferred quaternary derivative of noroxymorphone is methylnaltrexone. Methylnaltrexone is a quaternary amine derivative of naltrexone. Methylnaltrexone has been found to have only 2 to 4% of the opiate antagonistic activity of naltrexone in vivo due to its inability to pass the blood-brain-barrier and bind to the opiate receptors in the central nervous system.
- Opioids are typically administered at a morphine equivalent dosage of: 0.005 to 0.15 mg/kg body weight for intrathecal administration; 0.05 to 1.0 mg/kg body weight for intravenous administration; 0.05 to 1.0 mg/kg body weight for intramuscular administration; 0.05 to 1.0 mg/kg body weight/hour for transmucosal or transdermal administration. By “morphine equivalent dosage” is meant representative doses of other opioids which equal one milligram of morphine, for example 10 mg meperidine, 1 mg methadone, and 80 μg fentanyl.
- In accordance with the present invention, methylnaltrexone is administered at a dosage of: 0.03 to 1.0 mg/kg body weight for intravenous administration; 0.03 to 1.0 mg/kg body weight for intramuscular administration; 0.03 to 1.0 mg/kg body weight for transmucosal administration and 1.0 to 40.0 mg/kg body weight for oral administration. In accordance with the present invention, enteric coated methylnaltrexone, is administered at a dosage of 1.0 to 80.0 mg/kg body weight for oral administration.
- The administration of the methylnaltrexone is preferably commenced prior to administration of the opioid to prevent opioid-induced dysphoria, pruritus, urinary retention, inhibition of gastric emptying with enteric feeding, or constipation. It is desirable to commence administration of methylnaltrexone about 5 minutes for parenteral MNTX administration and 20 minutes for enteral MNTX administration prior to administration of opioids in order to prevent these opioid-induced side effects. It is also preferable to administer the methylnaltrexone prior to the onset of nonopioid-induced gastric dysfunction symptoms, inhibition of gastric emptying with enteric feeding or constipation, in order to prevent these symptoms from manifesting. While the prevention of symptoms is preferred, methylnaltrexone administration may also be commenced after the administration of the opioid or after the onset of opioid induced symptoms as a treatment for those symptoms.
- Methylnaltrexone is rapidly absorbed after oral administration from the stomach and bowel. Initial plasma levels of the drug are seen within 5-10 minutes of the administration of non-enteric coated compound. Addition of an enteric coating which prevents gastric absorption is associated with lower plasma levels of the methylnaltrexone. Surprisingly, the addition of an enteric coating (i.e., a coating which will prevent degradation or release in the stomach, but will release drug in the small and large bowel) appears to enhance the efficacy of methylnaltrexone in the prevention of decreases in gut motility by intravenously administered opioids (morphine).
- For intravenous administration, methylnaltrexone is formulated with saline or other physiologically acceptable carriers; for intramuscular administration, the methylnaltrexone is formulated with saline or other pharmacologically acceptable carriers; for transmucosal administration the methylnaltrexone is formulated with a sugar and cellulose mix or other pharmacologically acceptable carriers known in the art; and for oral administration, the methylnaltrexone is formulated with pharmacologically acceptable binders to make a tablet or capsule with or without an enteric coating. Methods for such formulations are well known to those skilled in the art.
- In a preferred embodiment for the prevention and/or treatment of constipation, the MNTX is enterically coated and administered orally.
- The enteric coating may be made of any suitable composition. Suitable enteric coatings are described, for example, in U.S. Pat. Nos. 4,311,833 to Namikoshi, et al.; 4,377,568 to Chopra; 4,385,078 to Onda, et al.; 4,457,907 to Porter; 4,462,839 to McGinley, et al.; 4,518,433 to McGinley, et al.; 4,556,552 to Porter, et al.; 4,606,909 to Bechgaard et al.; 4,615,885 to Nakagame, et al.; 4,670,287 to Tsuji; 5,536,507 TO Abramowitz, et al.; 5,567,423 to Ying, et al.; 5,591,433 to Michael, et al.; 5,597,564 to Ying, et al.; 5,609,871 to Michael, et al.; 5,614,222 to Kaplan; 5,626,875 to Rodes, et al.; and 5,629,001 to Michael, et al., all of which are incorporated herein by reference.
- Preferred enteric coating compositions include alkyl and hydroxyalkyl celluloses and their aliphatic esters, e.g., methylcellulose, ethylcellulose, hydroxyethylcellulose, hydroxypropylcellulose, hydroxybutylcellulose, hydroxyethylethylcellulose, hydroxyprophymethylcellulose, hydroxybutylmethylcellulose, hydroxypropylcellulose phthalate, hydroxypropylmethylcellulose phthalate and hydroxypropylmethylcellulose acetate succincate; carboxyalkylcelluloses and their salts, e.g., carboxymethylethylcellulose; cellulose acetate phthalate; cellulose acetate trimellitate, polycarboxymethylene and its salts and derivatives; polyvinylalcohol and its esters: polyvinyl acetate phthalate; polycarboxymethylene copolymer with sodium formaldehyde carboxylate; acrylic polymers and copolymers, e.g., methacrylic acid-methyl methacrylic acid copolymer and methacrylic acid-methyl acrylate copolymer; edible oils such as peanut oil, palm oil, olive oil and hydrogenated vegetable oils; polyvinylpyrrolidone; polyethyleneglycol and its esters: natural products such as shellac, and zein.
- Other preferred enteric coatings include polyvinylacetate esters, e.g., polyvinyl acetate phthalate; alkyleneglycolether esters of copolymers such as partial ethylene glycol monomethylether ester of ethylacrylate-maleic anhydride copolymer or diethyleneglycol monomethylether ester of methylacrylate-maleic anhydride copolymer, N-butylacrylate-maleic anhydride copolymer, isobutylacrylate-maleic anhydride copolymer or ethylacrylate-maleic anhydride copolymer; and polypeptides resistant to degradation in the gastric environment, e.g., polyarginine and polylysine.
- Mixtures of two or more of the above compounds may be used as desired. The presently preferred enteric coating comprises cellulose acetate phthalate.
- The enteric coating material may be mixed with various excipients including plasticizers such as triethyl citrate, acetyl triethyl citrate, diethyl phthalate, dibutyl phthalate, dibutyl subacute, dibutyl tartrate, dibutyl maleate, dibutyl succinate and diethyl succinate and inert fillers such as chalk or pigments.
- The composition and thickness of the enteric coating may be selected to dissolve immediately upon coated with the digestive juice of the intestine. Alternatively, the composition and thickness of the anterior coating may be selected to be a time-release coating which dissolves over a selected period of time, as is well known in the art.
- The amount of enteric coating depends on the particular enteric coating composition used and is preferably sufficient to substantially prevent the absorption of MNTX in the stomach.
- Hydroxyalkyl celluloses and their aliphatic esters, carboxyalkyl celluloses and their salts, polycarboxymethylene and its salts and derivatives, polyvinyl alcohol and its esters, polycarboxymethylene copolymer with sodium formaldehyde carboxylates, polyvinylpyrrolidone, and polyethylene glycol and its esters can be applied as enteric coatings by first dissolving the compound in a minimum amount of water. Alcohol is then added to the point of incipient cloudiness. The mixture can then be applied by conventional techniques.
- Application of cellulose acetate phthalate may be accomplished by simply dissolving the cellulose acetate phthalate in a minimum amount of alcohol and then applying by conventional techniques. Hydrogenated vegetable oils may be applied by first dissolving the oil in a minimal amount of a non-polymer solvent, such as methylene chloride, chloroform or carbon tetrachloride, then adding alcohol to the point of incipient cloudiness and then applying by conventional techniques.
- In a particularly preferred embodiment, the MNTX is coated with Eudragit L100 or S100, a methacrylic acid copolymer enteric coating, at a 50% coating level to provide stability at gastric pH and dissolution at gut pH per a US Pharmacopeia (USP) standard for enteric coatings.
- Any art-known transdermal application may be used, but transdermal administration is preferably via a patch applied to the skin with a membrane of sufficient permeability to allow diffusion of MNTX at a fixed rate in the range of 1.0 to 10.0 mg/hr. The rate of administration may be varied by varying the size of the membrane contact area and/or applying an electrical wiring potential to a drug reservoir. The patch preferably holds 25 mg to 1 gram of available drug in the reservoir plus additional drug as needed for the mechanics of the system.
- In the above description, methylnaltrexone is used as an example of a particularly effective QDNM. It is apparent that other QDNM's may be used as desired.
- The following Examples are intended to illustrate aspects of the invention and are not to be construed as limitations upon it. The methylnaltrexone used in the following Examples was manufactured by Mallinckrodt Pharmaceuticals, St. Louis, Mo. The Enteric Coating was manufactured by Coating Place, Inc., Verona, Wis.
- Ten patients were treated with morphine sulfate administered directly to the central nervous system or intravenously. The morphine sulfate was administered at 0.1 mg/kg body weight. The patients in the study had been treated for pain resulting from surgery. All the patients exhibited pruritus as a side effect of the morphine sulfate administration. Subsequent to the onset of the pruritus, methylnaltrexone, at a dosage of 0.3 mg/kg of body weight was administered intravenously as a saline solution containing methylnaltrexone in a concentration of 5 mg/ml to each of the patients. Eighty percent of the 10 patients exhibited relief from the pruritus sixty minutes after receiving methylnaltrexone.
- In a control group, 8 patients were treated with morphine sulfate administered directly to the central nervous system or intravenously. The morphine sulfate was administered at 0.1 mg/kg body weight. The patients in the study had been treated for pain resulting from surgery. All the patients exhibited pruritus as a side effect of the morphine sulfate administration. A placebo, saline at a volume equivalent to the volume administered to patients receiving active drug, was administered intravenously to each of the patients. Only 50% of the patients exhibited relief from the pruritus within sixty minutes.
- The study indicates that methylnaltrexone was effective in treating pruritus induced by morphine sulfate.
- Morphine (0.05) mg/kg intravenous) was administered to three volunteers after the oral administration of placebo, methylnaltrexone (6.4 mg/kg) in a gelatin capsule (which dissolves readily in the stomach), or methylnaltrexone after enteric coating (12.8 mg/kg of substance to yield a mass of 6.4 mg/kg methylnaltrexone incorporated) which has decreased release and absorption in the stomach. Oral-cecal transit time was measured using the lactulose-hydrogen breath test. Plasma levels of methylnaltrexone were measured and after the enteric coated preparation were lower. In each subject morphine alone increased the oral-cecal transit time by 20-70 minutes, methylnaltrexone blocked this effect, and enteric coated methylnaltrexone blocked the effect to a similar or greater extent than the uncoated methylnaltrexone.
- Two patients receiving morphine (375 mg/day and 18 mg/day) and receiving enteric tube feedings of 200 ml every four (4) hours were studied. The first patient had residual stomach contents of 50 cc to 100 cc, or 22.0-58.8% of administered feedings measured every 4 hours during a 24 hour control period. Prior to drug administration the residual volume had increased to 260 cc or >100% of previous feeding volume. Methylnaltrexone, 0.45 mg/kg, was administered intravenously every 4 hours for 24 hours, after the control period. After the first dose (4 hours) of MNTX, the residual was 150 cc or 58% of the previous bolus feed, after the 3rd dose (12 hours) the residual was 75 cc or 30% of the previous feed, after the 5th dose (20 hours) the residual was 22 cc or 13% of the previous feed and after the 6th and final dose (24 hours) the residual was 8 cc or 5.5% of previous feed. The follow-up residual sampling after the final drug-tube feed interval had increased to 50 cc or 38% or previous feed.
- The second patient had greater than 200 cc residual or 100% of previous feedings on two consecutive samplings, that is 8 hrs and 4 hrs before drug administration. After initiation of Methylnaltrexone, 0.45 mg/kg, administered intravenously every 4 hours, the first residual (4 hrs) was 0 cc, the second residual (8 hrs) was 24 cc or 15% of previous bolus feed.
- Subjects receiving morphine at a variety of doses (via patient controlled analgesia—PCA) who experience urinary retention are administered Methylnaltrexone 0.45 mg/kg intravenously or a placebo. Those treated with Methylnaltrexone have resolution of their symptoms, while those administered placebo go on to require additional therapy (usually urinary catheterization).
- In a double-blind randomized placebo-controlled study, we evaluated the efficacy of oral methylnaltrexone to decrease subjective effects after administering morphine to 10 normal human volunteers. After intravenous morphine injection (0.05 mg/kg), significant increases in subjective ratings were obtained on “nauseous”, “skin itch”, “stimulated”, and “flushing”. Compared to baseline, significant increases were obtained on “nauseous”, “skin itch”, “stimulated”, and “flushing” ratings after placebo and morphine administration (P<0.05, P<0.05, P<0.01 and P<0.01, respectively). Oral methylnaltrexone (19.2 mg/kg) significantly decreased these four ratings (P<0.05, P<0.05, P<0.01 and P<0.01, respectively) compared to placebo and morphine and resulted in no change when compared to baseline. Plasma methylnaltrexone concentrations were also measured and correlation between pharmacological effects of the compound and its plasma levels was shown. Our results indicate that methylnaltrexone decreases dysphoria and some other undesirable subjective effects associated with opioid medications.
- The preceding description and Examples are intended to be illustrative. Those skilled in the art to which the invention pertains will appreciate that alterations and changes in the described protocols may be practiced without departing from the meaning, spirit, and scope of this invention. Therefore, the foregoing description should be read consistent with and as support to the following claims, which are to have their fullest and fair scope.
Claims (15)
1-14. (canceled)
15. A method for treating a patient with constipation caused by endogenous opioids, comprising administering to the patient an amount of a quaternary derivative of noroxymorphone effective to treat the constipation.
16. The method of claim 15 , wherein the administration is parenteral.
17. The method of claim 15 , wherein the administration is intravenous.
18. The method of claim 15 , wherein the administration is intravenous. and the amount is between 0.03 and 1.0 mg/kg.
19. The method of claim 15 , wherein the administration is intramuscular and the amount is between 0.03 and 1.0 mg/kg.
20. The method of claim 15 , wherein the administration is oral.
21. The method of claims 15 -20, wherein the quaternary derivative or noroxymorphone is methylnaltrexone.
22. A method for preventing in a patient constipation caused by endogenous opioids, comprising administering to the patient an amount of a quaternary derivative of noroxymorphone effective to treat the constipation.
23. The method of claim 22 , wherein the administration is parenteral.
24. The method of claim 22 , wherein the administration is intravenous.
25. The method of claim 22 , wherein the administration is intravenous and the amount is between 0.03 and 1.0 mg/kg.
26. The method of claim 22 , wherein the administration is intramuscular and the amount is between 0.03 and 1.0 mg/kg.
27. The method of claim 22 , wherein the administration is oral.
28. The method of claims 22 -28, wherein the quaternary derivative or noroxymorphone is methylnaltrexone.
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12/333,912 US20090312359A1 (en) | 1997-11-03 | 2008-12-12 | Use of methylnaltrexone and related compounds for treatment of gastrointestinal dysfunction induced by endogenous opioids |
Applications Claiming Priority (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US08/962,742 US5972954A (en) | 1997-11-03 | 1997-11-03 | Use of methylnaltrexone and related compounds |
US09/120,703 US6274591B1 (en) | 1997-11-03 | 1998-07-22 | Use of methylnaltrexone and related compounds |
US09/862,169 US6608075B2 (en) | 1997-11-03 | 2001-05-21 | Use of methylnaltrexone and related compounds |
US10/278,630 US20030065003A1 (en) | 1997-11-03 | 2002-10-23 | Use of methylnaltrexone and related compounds |
US10/779,129 US20040162308A1 (en) | 1997-11-03 | 2004-02-12 | Use of methylnaltrexone and related compounds for treatment of constipation caused by endogenous opioids |
US12/333,912 US20090312359A1 (en) | 1997-11-03 | 2008-12-12 | Use of methylnaltrexone and related compounds for treatment of gastrointestinal dysfunction induced by endogenous opioids |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US10/779,129 Continuation US20040162308A1 (en) | 1997-11-03 | 2004-02-12 | Use of methylnaltrexone and related compounds for treatment of constipation caused by endogenous opioids |
Publications (1)
Publication Number | Publication Date |
---|---|
US20090312359A1 true US20090312359A1 (en) | 2009-12-17 |
Family
ID=26818669
Family Applications (6)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/120,703 Expired - Lifetime US6274591B1 (en) | 1997-11-03 | 1998-07-22 | Use of methylnaltrexone and related compounds |
US09/862,169 Expired - Lifetime US6608075B2 (en) | 1997-11-03 | 2001-05-21 | Use of methylnaltrexone and related compounds |
US10/278,630 Abandoned US20030065003A1 (en) | 1997-11-03 | 2002-10-23 | Use of methylnaltrexone and related compounds |
US10/779,129 Abandoned US20040162308A1 (en) | 1997-11-03 | 2004-02-12 | Use of methylnaltrexone and related compounds for treatment of constipation caused by endogenous opioids |
US10/962,729 Abandoned US20050048117A1 (en) | 1997-11-03 | 2004-10-12 | Use of methylnaltrexone and related compounds |
US12/333,912 Abandoned US20090312359A1 (en) | 1997-11-03 | 2008-12-12 | Use of methylnaltrexone and related compounds for treatment of gastrointestinal dysfunction induced by endogenous opioids |
Family Applications Before (5)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US09/120,703 Expired - Lifetime US6274591B1 (en) | 1997-11-03 | 1998-07-22 | Use of methylnaltrexone and related compounds |
US09/862,169 Expired - Lifetime US6608075B2 (en) | 1997-11-03 | 2001-05-21 | Use of methylnaltrexone and related compounds |
US10/278,630 Abandoned US20030065003A1 (en) | 1997-11-03 | 2002-10-23 | Use of methylnaltrexone and related compounds |
US10/779,129 Abandoned US20040162308A1 (en) | 1997-11-03 | 2004-02-12 | Use of methylnaltrexone and related compounds for treatment of constipation caused by endogenous opioids |
US10/962,729 Abandoned US20050048117A1 (en) | 1997-11-03 | 2004-10-12 | Use of methylnaltrexone and related compounds |
Country Status (5)
Country | Link |
---|---|
US (6) | US6274591B1 (en) |
EP (1) | EP1047426B1 (en) |
AU (1) | AU758416B2 (en) |
CA (1) | CA2312234C (en) |
WO (1) | WO1999022737A1 (en) |
Cited By (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8003794B2 (en) | 2005-05-25 | 2011-08-23 | Progenics Pharmaceuticals, Inc. | (S)-N-methylnaltrexone |
US8247425B2 (en) | 2008-09-30 | 2012-08-21 | Wyeth | Peripheral opioid receptor antagonists and uses thereof |
US8338446B2 (en) | 2007-03-29 | 2012-12-25 | Wyeth Llc | Peripheral opioid receptor antagonists and uses thereof |
US8343992B2 (en) | 2005-05-25 | 2013-01-01 | Progenics Pharmaceuticals, Inc. | Synthesis of R-N-methylnaltrexone |
US8471022B2 (en) | 2008-02-06 | 2013-06-25 | Progenics Pharmaceuticals, Inc. | Preparation and use of (R),(R)-2,2′-bis-methylnaltrexone |
US8546418B2 (en) | 2007-03-29 | 2013-10-01 | Progenics Pharmaceuticals, Inc. | Peripheral opioid receptor antagonists and uses thereof |
US8552025B2 (en) | 2003-04-08 | 2013-10-08 | Progenics Pharmaceuticals, Inc. | Stable methylnaltrexone preparation |
US8637538B1 (en) | 2012-12-14 | 2014-01-28 | Trevi Therapeutics, Inc. | Methods for treatment of pruritis |
US8940753B1 (en) | 2012-12-14 | 2015-01-27 | Trevi Therapeutics, Inc. | Methods for treating pruritis |
US8987289B2 (en) | 2012-12-14 | 2015-03-24 | Trevi Therapeutics, Inc. | Methods for treating pruritus |
US9102680B2 (en) | 2007-03-29 | 2015-08-11 | Wyeth Llc | Crystal forms of (R)-N-methylnaltrexone bromide and uses thereof |
US10307417B2 (en) | 2010-03-11 | 2019-06-04 | Wyeth, Llc | Oral formulations and lipophilic salts of methylnaltrexone |
US11660296B2 (en) | 2018-07-23 | 2023-05-30 | Trevi Therapeutics, Inc. | Treatment of chronic cough, breathlessness and dyspnea |
Families Citing this family (46)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6559158B1 (en) * | 1997-11-03 | 2003-05-06 | Ur Labs, Inc. | Use of methylnaltrexone and related compounds to treat chronic opioid use side affects |
US20030158220A1 (en) * | 1997-11-03 | 2003-08-21 | Foss Joseph F. | Use of methylnaltrexone and related compounds to treat chronic opioid use side effects |
US6274591B1 (en) * | 1997-11-03 | 2001-08-14 | Joseph F. Foss | Use of methylnaltrexone and related compounds |
US6375957B1 (en) | 1997-12-22 | 2002-04-23 | Euro-Celtique, S.A. | Opioid agonist/opioid antagonist/acetaminophen combinations |
KR100417489B1 (en) | 1997-12-22 | 2004-02-05 | 유로-셀티크 소시에떼 아노뉨 | Opioid agonist/antagonist combinations |
AU6934400A (en) * | 1999-08-25 | 2001-03-19 | Barrett R. Cooper | Compositions and methods for treating opiate intolerance |
US6451806B2 (en) | 1999-09-29 | 2002-09-17 | Adolor Corporation | Methods and compositions involving opioids and antagonists thereof |
PT1225897E (en) * | 1999-11-01 | 2005-01-31 | John Rhodes | COMPOSITION FOR THE TREATMENT OF OBSTIPACY AND IRRITAVEL INTESTINAL SYNDROME |
EP1244448B1 (en) | 1999-11-29 | 2009-05-27 | Adolor Corporation | Novel methods for the treatment and prevention of ileus |
US6469030B2 (en) | 1999-11-29 | 2002-10-22 | Adolor Corporation | Methods for the treatment and prevention of ileus |
DK1299104T3 (en) | 2000-02-08 | 2009-08-03 | Euro Celtique Sa | Oral opioid agonist formulations secured against forgery |
DE10059415A1 (en) | 2000-11-30 | 2002-06-06 | Gruenenthal Gmbh | Use of weak opioids and mixed opioid agonists / antagonists for the treatment of urinary incontinence |
US20030065002A1 (en) | 2001-05-11 | 2003-04-03 | Endo Pharmaceuticals, Inc. | Abuse-resistant controlled-release opioid dosage form |
CA2449175A1 (en) * | 2001-06-05 | 2002-12-12 | University Of Chicago | Use of methylnaltrexone to treat immune suppression |
JP4256259B2 (en) | 2001-07-18 | 2009-04-22 | ユーロ−セルティーク エス.エイ. | Pharmaceutical formulation of oxycodone and naloxone |
AU2002323032B2 (en) | 2001-08-06 | 2005-02-24 | Euro-Celtique S.A. | Opioid agonist formulations with releasable and sequestered antagonist |
US20040259898A1 (en) * | 2002-02-04 | 2004-12-23 | Jonathan Moss | Use of methylnaltrexone in treating gastrointestinal dysfunction in equines |
CA2708900C (en) | 2002-04-05 | 2019-06-04 | Purdue Pharma | Pharmaceutical preparation containing oxycodone and naloxone |
ES2358151T3 (en) * | 2002-08-15 | 2011-05-06 | Euro-Celtique S.A. | PHARMACEUTICAL COMPOSITIONS THAT INCLUDE AN OPIOID ANTAGONIST. |
MXPA05010819A (en) * | 2003-04-08 | 2006-03-30 | Progenics Pharm Inc | The use of peripheral opiois antagonists, especially methylnaltrexone to treat irritable bowel syndrome. |
CA2521420A1 (en) * | 2003-04-08 | 2004-10-28 | Progenics Pharmaceuticals, Inc. | Combination therapy for constipation comprising a laxative and a peripheral opioid antagonist |
MY135852A (en) | 2003-04-21 | 2008-07-31 | Euro Celtique Sa | Pharmaceutical products |
CA2536816A1 (en) * | 2003-08-12 | 2005-03-03 | Endo Pharmaceuticals, Inc. | Method for deterring abuse of opioids by combination with non-release formulation of emetic |
CA2539027C (en) * | 2003-09-25 | 2010-02-23 | Euro-Celtique S.A. | Pharmaceutical combinations of hydrocodone and naltrexone |
CA2594987A1 (en) * | 2004-12-14 | 2006-06-22 | Shionogi & Co., Ltd. | Therapeutic agent for constipation |
BRPI0606587A2 (en) * | 2005-01-20 | 2009-07-07 | Progenics Pharmaceuticais Inc | use of methylnaltrexone and related compounds to treat postoperative gastrointestinal dysfunction |
EP1702558A1 (en) | 2005-02-28 | 2006-09-20 | Euro-Celtique S.A. | Method and device for the assessment of bowel function |
US8518962B2 (en) | 2005-03-07 | 2013-08-27 | The University Of Chicago | Use of opioid antagonists |
US9662325B2 (en) | 2005-03-07 | 2017-05-30 | The University Of Chicago | Use of opioid antagonists to attenuate endothelial cell proliferation and migration |
MX2007010833A (en) | 2005-03-07 | 2009-02-17 | Univ Chicago | Use of opioid antagonists to attenuate endothelial cell proliferation and migration. |
US8524731B2 (en) | 2005-03-07 | 2013-09-03 | The University Of Chicago | Use of opioid antagonists to attenuate endothelial cell proliferation and migration |
US20080194611A1 (en) * | 2005-06-03 | 2008-08-14 | Alverdy John C | Modulation of Cell Barrier Dysfunction |
US20070185145A1 (en) * | 2006-02-03 | 2007-08-09 | Royds Robert B | Pharmaceutical composition containing a central opioid agonist, a central opioid antagonist, and a peripheral opioid antagonist, and method for making the same |
US20080027579A1 (en) * | 2006-07-31 | 2008-01-31 | Van Der Hoop Roland Gerritsen | Dosage limiting medication dispensing method and apparatus |
TW200815451A (en) * | 2006-08-04 | 2008-04-01 | Wyeth Corp | 6-carboxy-normorphinan derivatives, synthesis and uses thereof |
TW200817048A (en) * | 2006-09-08 | 2008-04-16 | Wyeth Corp | Dry powder compound formulations and uses thereof |
US8383649B2 (en) * | 2007-07-11 | 2013-02-26 | Mallinckrodt Llc | Crystalline forms of naltrexone methobromide |
US8748448B2 (en) | 2007-10-18 | 2014-06-10 | Aiko Biotechnology | Combination analgesic employing opioid agonist and neutral antagonist |
US8883817B2 (en) * | 2007-10-18 | 2014-11-11 | Aiko Biotechnology | Combination analgesic employing opioid and neutral antagonist |
US8685995B2 (en) | 2008-03-21 | 2014-04-01 | The University Of Chicago | Treatment with opioid antagonists and mTOR inhibitors |
WO2010002576A1 (en) | 2008-07-01 | 2010-01-07 | University Of Chicago | Particles containing an opioid receptor antagonist and methods of use |
PT2405915T (en) | 2009-03-10 | 2019-01-29 | Euro Celtique Sa | Immediate release pharmaceutical compositions comprising oxycodone and naloxone |
MY183489A (en) | 2013-07-23 | 2021-02-22 | Euro Celtique Sa | A combination of oxycodone and naloxone for use in treating pain in patients suffering from pain and a disease resulting in intestinal dysbiosis and/or increasing the risk for intestinal bacterial translocation |
WO2016061531A1 (en) | 2014-10-17 | 2016-04-21 | Salix Pharmaceuticals, Inc. | Use of methylnaltrexone to attenuate tumor progression |
EP3965731A1 (en) | 2019-05-07 | 2022-03-16 | Bausch Health Ireland Limited | Liquid oral dosage formulations of methylnaltrexone |
CA3177250A1 (en) | 2020-05-02 | 2021-11-11 | Bausch Health Ireland Limited | Methods of reducing mortality risk in subjects suffering from an underlying disease or condition by administration of methylnaltrexone |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4176186A (en) * | 1978-07-28 | 1979-11-27 | Boehringer Ingelheim Gmbh | Quaternary derivatives of noroxymorphone which relieve intestinal immobility |
US4719215A (en) * | 1986-03-07 | 1988-01-12 | University Of Chicago | Quaternary derivatives of noroxymorphone which relieve nausea and emesis |
US6559158B1 (en) * | 1997-11-03 | 2003-05-06 | Ur Labs, Inc. | Use of methylnaltrexone and related compounds to treat chronic opioid use side affects |
US6608075B2 (en) * | 1997-11-03 | 2003-08-19 | The University Of Chicago | Use of methylnaltrexone and related compounds |
Family Cites Families (75)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US222911A (en) * | 1879-12-23 | Improvement in book-cases | ||
US2003A (en) * | 1841-03-12 | Improvement in horizontal windivhlls | ||
US1047726A (en) * | 1912-03-12 | 1912-12-17 | Anthony J Yoggerst | Pipe-cleaner. |
US2625457A (en) * | 1951-07-26 | 1953-01-13 | Bernard J Baecher | Course recorder |
JPS5535031A (en) | 1978-09-04 | 1980-03-11 | Shin Etsu Chem Co Ltd | Enteric coating composition |
US4311833A (en) | 1979-03-06 | 1982-01-19 | Daicel Chemical Industries Ltd. | Process for preparing ethylcarboxymethylcellulose |
US4322426A (en) * | 1980-04-28 | 1982-03-30 | E. I. Du Pont De Nemours And Company | 17-Substituted-6-desoxy-7,8-dihydro-6α-methylnoroxymorphone narcotic antagonists |
US4377568A (en) | 1981-08-12 | 1983-03-22 | Merck Sharp & Dohme (I.A.) Corp. | Preparation of aqueous alcoholic dispersions of pH sensitive polymers and plasticizing agents and a method of enteric coating dosage forms using same |
DK150008C (en) | 1981-11-20 | 1987-05-25 | Benzon As Alfred | PROCEDURE FOR THE PREPARATION OF A PHARMACEUTICAL ORAL POLYDEPOT PREPARATION |
US4987136A (en) | 1982-03-16 | 1991-01-22 | The Rockefeller University | Method for controlling gastrointestinal dysmotility |
DE3381877D1 (en) | 1982-03-16 | 1990-10-18 | Univ Rockefeller | USE OF OPIUM ANTAGONISTS FOR THE PRODUCTION OF MEDICINAL PRODUCTS FOR THE REMEDY OF GASTRO-INTESTINAL DISORDERS. |
US4457907A (en) | 1982-08-05 | 1984-07-03 | Clear Lake Development Group | Composition and method for protecting a therapeutic drug |
US4518433A (en) | 1982-11-08 | 1985-05-21 | Fmc Corporation | Enteric coating for pharmaceutical dosage forms |
US4462839A (en) | 1983-06-16 | 1984-07-31 | Fmc Corporation | Enteric coating for pharmaceutical dosage forms |
US4556552A (en) | 1983-09-19 | 1985-12-03 | Colorcon, Inc. | Enteric film-coating compositions |
US4615885A (en) | 1983-11-01 | 1986-10-07 | Terumo Kabushiki Kaisha | Pharmaceutical composition containing urokinase |
US5266574A (en) | 1984-04-09 | 1993-11-30 | Ian S. Zagon | Growth regulation and related applications of opioid antagonists |
JPS6229515A (en) | 1985-07-30 | 1987-02-07 | Shinjiro Tsuji | Method for film-coating of hard capsule |
US4861781A (en) * | 1986-03-07 | 1989-08-29 | The University Of Chicago | Quaternary derivatives of noroxymorphone which relieve nausea and emesis |
WO1988001512A1 (en) | 1986-08-28 | 1988-03-10 | Thomas Ko Sai Ying | Animal growth promotant |
US5597564A (en) | 1986-08-28 | 1997-01-28 | Enzacor Properties Limited | Method of administering a microgranular preparation to the intestinal region of animals |
US4888346A (en) * | 1986-10-07 | 1989-12-19 | Bernard Bihari | Method for the treatment of persons infected with HTLV-III (AIDS) virus |
FR2609632B1 (en) | 1987-01-21 | 1991-03-29 | Shelly Marc | NOVEL THERAPEUTIC APPLICATION OF 17- (CYCLOPROPYLMETHYL) -4,5-EPOXY-3,14-DIHYDROXYMORPHINON-6-ONE AND PHARMACEUTICAL COMPOSITIONS FOR THIS USE |
US4857833A (en) * | 1987-08-27 | 1989-08-15 | Teradyne, Inc. | Diagnosis of faults on circuit board |
CA1315689C (en) | 1987-09-03 | 1993-04-06 | Leon I. Goldberg | Quarternary derivatives of noroxymorphone which relieve nausea and emesis |
ATE78687T1 (en) * | 1987-09-10 | 1992-08-15 | Univ Chicago | QUATERNARY DERIVATIVES OF NOROXYMORPHONE FOR THE TREATMENT OF NAUSEA AND VOMITING. |
EP0352361A1 (en) | 1988-07-29 | 1990-01-31 | The Rockefeller University | Method of treating patients suffering from chronic pain or chronic cough |
US5102887A (en) * | 1989-02-17 | 1992-04-07 | Arch Development Corporation | Method for reducing emesis and nausea induced by the administration of an emesis causing agent |
US4965269A (en) * | 1989-12-20 | 1990-10-23 | Ab Hassle | Therapeutically active chloro substituted benzimidazoles |
JPH04230625A (en) * | 1990-12-27 | 1992-08-19 | Standard Chem & Pharmaceut Corp Ltd | Method for production of finely dispersed tablet composition consisting of microcapsule containing sprayed and dried sodium dichlofenac and having enteric coating |
US5270328A (en) | 1991-03-29 | 1993-12-14 | Eli Lilly And Company | Peripherally selective piperidine opioid antagonists |
US5159081A (en) * | 1991-03-29 | 1992-10-27 | Eli Lilly And Company | Intermediates of peripherally selective n-carbonyl-3,4,4-trisubstituted piperidine opioid antagonists |
CA2110899C (en) | 1991-06-21 | 2006-08-08 | Jacob G. Michael | Orally administrable therapeutic proteins and method of making |
US5614219A (en) * | 1991-12-05 | 1997-03-25 | Alfatec-Pharma Gmbh | Oral administration form for peptide pharmaceutical substances, in particular insulin |
US6096756A (en) | 1992-09-21 | 2000-08-01 | Albert Einstein College Of Medicine Of Yeshiva University | Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists |
US5512578A (en) | 1992-09-21 | 1996-04-30 | Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University | Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by exogenous and endogenous opiod agonists |
US5472943A (en) | 1992-09-21 | 1995-12-05 | Albert Einstein College Of Medicine Of Yeshiva University, | Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other opioid agonists |
US5580876A (en) | 1992-09-21 | 1996-12-03 | Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University | Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by morphine and other bimodally-acting opioid agonists |
USRE36547E (en) | 1992-09-21 | 2000-02-01 | Albert Einstein College Of Medicine Of Yeshiva University | Method of simultaneously enhancing analgesic potency and attenuating dependence liability caused by exogenous and endogenous opioid agonists |
ATE143803T1 (en) | 1992-12-22 | 1996-10-15 | Univ Cincinnati | ORAL ADMINISTRATION OF IMMUNOLOGICALLY ACTIVE BIOMOLECULES AND OTHER THERAPEUTIC PROTEINS |
US5585348A (en) | 1993-02-10 | 1996-12-17 | Albert Einstein College Of Medicine Of Yeshiva University, A Division Of Yeshiva University | Use of excitatory opioid receptor antagonists to prevent growth factor-induced hyperalgesia |
US5656290A (en) * | 1993-02-26 | 1997-08-12 | The Procter & Gamble Company | Bisacodyl dosage form with multiple enteric polymer coatings for colonic delivery |
US5391372A (en) * | 1993-06-28 | 1995-02-21 | Campbell; Elizabeth | Methods of treating colic and founder in horses |
AU2360195A (en) * | 1994-05-05 | 1995-11-29 | Beckman Instruments, Inc. | Oligonucleotide repeat arrays |
IT1269826B (en) | 1994-05-24 | 1997-04-15 | Paolo Minoia | USE OF OPTIACEAN ANTAGONISTS AND CALCIUM SALTS FOR THE PREPARATION OF MEDICATIONS FOR THE TREATMENT OF ENDORPHINE-MEDIATED PATHOLOGICAL FORMS |
US5536507A (en) | 1994-06-24 | 1996-07-16 | Bristol-Myers Squibb Company | Colonic drug delivery system |
US5866154A (en) * | 1994-10-07 | 1999-02-02 | The Dupont Merck Pharmaceutical Company | Stabilized naloxone formulations |
US5614222A (en) | 1994-10-25 | 1997-03-25 | Kaplan; Milton R. | Stable aqueous drug suspensions and methods for preparation thereof |
US5965161A (en) | 1994-11-04 | 1999-10-12 | Euro-Celtique, S.A. | Extruded multi-particulates |
ES2094694B1 (en) | 1995-02-01 | 1997-12-16 | Esteve Quimica Sa | NEW PHARMACEUTICALLY STABLE FORMULATION OF A COMPOUND OF BENZMIDAZOLE AND ITS PROCESS OF OBTAINING. |
US6025154A (en) * | 1995-06-06 | 2000-02-15 | Human Genome Sciences, Inc. | Polynucleotides encoding human G-protein chemokine receptor HDGNR10 |
US5804595A (en) * | 1995-12-05 | 1998-09-08 | Regents Of The University Of Minnesota | Kappa opioid receptor agonists |
DK0914097T3 (en) | 1996-03-12 | 2002-04-29 | Alza Corp | Composition and dosage form comprising opioid antagonist |
DE19651551C2 (en) | 1996-12-11 | 2000-02-03 | Klinge Co Chem Pharm Fab | Opioid antagonist-containing galenic formulation |
US6353004B1 (en) * | 1997-07-14 | 2002-03-05 | Adolor Coporation | Peripherally acting anti-pruritic opiates |
US20030158220A1 (en) * | 1997-11-03 | 2003-08-21 | Foss Joseph F. | Use of methylnaltrexone and related compounds to treat chronic opioid use side effects |
US5972954A (en) | 1997-11-03 | 1999-10-26 | Arch Development Corporation | Use of methylnaltrexone and related compounds |
US6194382B1 (en) | 1999-03-03 | 2001-02-27 | Albert Einstein College Of Medicine Of Yeshiva University | Method and composition for treating irritable bowel syndrome using low doses of opioid receptor antagonists |
AU6934400A (en) | 1999-08-25 | 2001-03-19 | Barrett R. Cooper | Compositions and methods for treating opiate intolerance |
US6451806B2 (en) | 1999-09-29 | 2002-09-17 | Adolor Corporation | Methods and compositions involving opioids and antagonists thereof |
US6469030B2 (en) | 1999-11-29 | 2002-10-22 | Adolor Corporation | Methods for the treatment and prevention of ileus |
EP1244448B1 (en) | 1999-11-29 | 2009-05-27 | Adolor Corporation | Novel methods for the treatment and prevention of ileus |
EP1244447B1 (en) | 1999-11-29 | 2007-01-10 | Adolor Corporation | Novel methods and compositions involving opioids and antagonists thereof |
AU4136901A (en) | 1999-11-29 | 2001-06-18 | Adolor Corporation | Novel methods for the treatment and prevention of dizziness and pruritus |
US6967075B2 (en) * | 2000-04-07 | 2005-11-22 | Schering Corporation | HCV replicase complexes |
EP1284736A2 (en) | 2000-05-05 | 2003-02-26 | Pain Therapeutics, Inc. | Opioid antagonist compositions and dosage forms |
CA2410371C (en) * | 2000-06-22 | 2015-11-17 | University Of Iowa Research Foundation | Methods for enhancing antibody-induced cell lysis and treating cancer |
CA2449175A1 (en) * | 2001-06-05 | 2002-12-12 | University Of Chicago | Use of methylnaltrexone to treat immune suppression |
SI1436012T1 (en) * | 2001-10-18 | 2018-03-30 | Nektar Therapeutics | Polymer conjugates of opioid antagonists |
US20030191147A1 (en) * | 2002-04-09 | 2003-10-09 | Barry Sherman | Opioid antagonist compositions and dosage forms |
US20040266806A1 (en) * | 2003-04-08 | 2004-12-30 | Sanghvi Suketu P. | Pharmaceutical formulation |
MXPA05010819A (en) * | 2003-04-08 | 2006-03-30 | Progenics Pharm Inc | The use of peripheral opiois antagonists, especially methylnaltrexone to treat irritable bowel syndrome. |
CA2521420A1 (en) * | 2003-04-08 | 2004-10-28 | Progenics Pharmaceuticals, Inc. | Combination therapy for constipation comprising a laxative and a peripheral opioid antagonist |
JP2007509722A (en) * | 2003-10-29 | 2007-04-19 | アレズ フィジオニックス リミテッド | Method and apparatus for determining the flow centerline of an ultrasonic fluid |
BRPI0606587A2 (en) * | 2005-01-20 | 2009-07-07 | Progenics Pharmaceuticais Inc | use of methylnaltrexone and related compounds to treat postoperative gastrointestinal dysfunction |
-
1998
- 1998-07-22 US US09/120,703 patent/US6274591B1/en not_active Expired - Lifetime
- 1998-11-03 CA CA002312234A patent/CA2312234C/en not_active Expired - Lifetime
- 1998-11-03 WO PCT/US1998/023485 patent/WO1999022737A1/en active IP Right Grant
- 1998-11-03 EP EP98957573A patent/EP1047426B1/en not_active Expired - Lifetime
- 1998-11-03 AU AU13802/99A patent/AU758416B2/en not_active Expired
-
2001
- 2001-05-21 US US09/862,169 patent/US6608075B2/en not_active Expired - Lifetime
-
2002
- 2002-10-23 US US10/278,630 patent/US20030065003A1/en not_active Abandoned
-
2004
- 2004-02-12 US US10/779,129 patent/US20040162308A1/en not_active Abandoned
- 2004-10-12 US US10/962,729 patent/US20050048117A1/en not_active Abandoned
-
2008
- 2008-12-12 US US12/333,912 patent/US20090312359A1/en not_active Abandoned
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4176186A (en) * | 1978-07-28 | 1979-11-27 | Boehringer Ingelheim Gmbh | Quaternary derivatives of noroxymorphone which relieve intestinal immobility |
US4719215A (en) * | 1986-03-07 | 1988-01-12 | University Of Chicago | Quaternary derivatives of noroxymorphone which relieve nausea and emesis |
US6559158B1 (en) * | 1997-11-03 | 2003-05-06 | Ur Labs, Inc. | Use of methylnaltrexone and related compounds to treat chronic opioid use side affects |
US6608075B2 (en) * | 1997-11-03 | 2003-08-19 | The University Of Chicago | Use of methylnaltrexone and related compounds |
Cited By (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8552025B2 (en) | 2003-04-08 | 2013-10-08 | Progenics Pharmaceuticals, Inc. | Stable methylnaltrexone preparation |
US10376584B2 (en) | 2003-04-08 | 2019-08-13 | Progenics Pharmaceuticals, Inc. | Stable pharmaceutical formulations of methylnaltrexone |
US9669096B2 (en) | 2003-04-08 | 2017-06-06 | Progenics Pharmaceuticals, Inc. | Stable pharmaceutical formulations of methylnaltrexone |
US8916581B2 (en) | 2005-05-25 | 2014-12-23 | Progenics Pharmaceuticals, Inc. | (S)-N-methylnaltrexone |
US8343992B2 (en) | 2005-05-25 | 2013-01-01 | Progenics Pharmaceuticals, Inc. | Synthesis of R-N-methylnaltrexone |
US9597327B2 (en) | 2005-05-25 | 2017-03-21 | Progenics Pharmaceuticals, Inc. | Synthesis of (R)-N-methylnaltrexone |
US8003794B2 (en) | 2005-05-25 | 2011-08-23 | Progenics Pharmaceuticals, Inc. | (S)-N-methylnaltrexone |
US9102680B2 (en) | 2007-03-29 | 2015-08-11 | Wyeth Llc | Crystal forms of (R)-N-methylnaltrexone bromide and uses thereof |
US9879024B2 (en) | 2007-03-29 | 2018-01-30 | Progenics Pharmaceuticals., Inc. | Crystal forms of (R)-N-methylnaltrexone bromide and uses thereof |
US8546418B2 (en) | 2007-03-29 | 2013-10-01 | Progenics Pharmaceuticals, Inc. | Peripheral opioid receptor antagonists and uses thereof |
US8338446B2 (en) | 2007-03-29 | 2012-12-25 | Wyeth Llc | Peripheral opioid receptor antagonists and uses thereof |
US8772310B2 (en) | 2007-03-29 | 2014-07-08 | Wyeth Llc | Peripheral opioid receptor antagonists and uses thereof |
US8853232B2 (en) | 2007-03-29 | 2014-10-07 | Wyeth Llc | Peripheral opioid receptor antagonists and uses thereof |
US8471022B2 (en) | 2008-02-06 | 2013-06-25 | Progenics Pharmaceuticals, Inc. | Preparation and use of (R),(R)-2,2′-bis-methylnaltrexone |
US8916706B2 (en) | 2008-02-06 | 2014-12-23 | Progenics Pharmaceuticals, Inc. | Preparation and use of (R),(R)-2,2′-bis-methylnaltrexone |
US9724343B2 (en) | 2008-09-30 | 2017-08-08 | Wyeth, Llc | Peripheral opioid receptor antagonists and uses thereof |
US8420663B2 (en) | 2008-09-30 | 2013-04-16 | Wyeth | Peripheral opioid receptor antagonists and uses thereof |
US8247425B2 (en) | 2008-09-30 | 2012-08-21 | Wyeth | Peripheral opioid receptor antagonists and uses thereof |
US9180125B2 (en) | 2008-09-30 | 2015-11-10 | Wyeth, Llc | Peripheral opioid receptor antagonists and uses thereof |
US9492445B2 (en) | 2008-09-30 | 2016-11-15 | Wyeth, Llc | Peripheral opioid receptor antagonists and uses thereof |
US8822490B2 (en) | 2008-09-30 | 2014-09-02 | Wyeth Llc | Peripheral opioid receptor antagonists and uses thereof |
US8455644B2 (en) | 2008-09-30 | 2013-06-04 | Wyeth | Peripheral opioid receptor antagonists and uses thereof |
US10307417B2 (en) | 2010-03-11 | 2019-06-04 | Wyeth, Llc | Oral formulations and lipophilic salts of methylnaltrexone |
US10376505B2 (en) | 2010-03-11 | 2019-08-13 | Wyeth, Llc | Oral formulations and lipophilic salts of methylnaltrexone |
US10507206B2 (en) | 2010-03-11 | 2019-12-17 | Wyeth, Llc | Oral formulations and lipophilic salts of methylnaltrexone |
US8987289B2 (en) | 2012-12-14 | 2015-03-24 | Trevi Therapeutics, Inc. | Methods for treating pruritus |
US8637538B1 (en) | 2012-12-14 | 2014-01-28 | Trevi Therapeutics, Inc. | Methods for treatment of pruritis |
US10238646B2 (en) | 2012-12-14 | 2019-03-26 | Trevi Therapeutics Inc. | Methods for treating pruritus |
US8940753B1 (en) | 2012-12-14 | 2015-01-27 | Trevi Therapeutics, Inc. | Methods for treating pruritis |
US11660296B2 (en) | 2018-07-23 | 2023-05-30 | Trevi Therapeutics, Inc. | Treatment of chronic cough, breathlessness and dyspnea |
Also Published As
Publication number | Publication date |
---|---|
US20020028825A1 (en) | 2002-03-07 |
US20030065003A1 (en) | 2003-04-03 |
CA2312234C (en) | 2005-03-22 |
US20040162308A1 (en) | 2004-08-19 |
CA2312234A1 (en) | 1999-05-14 |
WO1999022737A1 (en) | 1999-05-14 |
US20050048117A1 (en) | 2005-03-03 |
EP1047426B1 (en) | 2010-05-12 |
EP1047426A4 (en) | 2004-07-14 |
AU758416B2 (en) | 2003-03-20 |
AU1380299A (en) | 1999-05-24 |
EP1047426A1 (en) | 2000-11-02 |
US6608075B2 (en) | 2003-08-19 |
US6274591B1 (en) | 2001-08-14 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US5972954A (en) | Use of methylnaltrexone and related compounds | |
US20090312359A1 (en) | Use of methylnaltrexone and related compounds for treatment of gastrointestinal dysfunction induced by endogenous opioids | |
EP1225897B1 (en) | Composition for treatment of constipation and irritable bowel syndrome | |
US6559158B1 (en) | Use of methylnaltrexone and related compounds to treat chronic opioid use side affects | |
US20120190702A1 (en) | Use of methylnaltrexone and related compounds to treat constipation in chronic opioid users | |
US8039456B2 (en) | Method of stimulating the motility of the gastrointestinal system using ipamorelin | |
JP2004512260A (en) | Local anesthesia / opioid preparation and method of use | |
WO2000001377A2 (en) | Nalmefene in combination with opioid analgesics | |
US20090312358A1 (en) | Method for management of diarrhea | |
CN110101702A (en) | System and method for treating bad pharmacodynamics response caused by opioid | |
AU782523B2 (en) | Salts and bases of 17-(cyclopropylmethyl)-4,5 alpha-epoxy-6-methylenemorphinan-3,14 diol for optimizing dopamine homeostasis during administration of opioid analgesics | |
US20050011468A1 (en) | Use of methylnaltrexone in treating gastrointestinal dysfunction in equines | |
US20040259898A1 (en) | Use of methylnaltrexone in treating gastrointestinal dysfunction in equines | |
AU2003204844B2 (en) | Use of methylnaltrexone and related compounds | |
EP2234630A1 (en) | Method of stimulating the motility of the gastrointestinal system using ipamorelin | |
CA2811285A1 (en) | Methods of converting a patient's treatment regimen from intravenous administration of an opioid to oral co-administration of morphine and oxycodone using a dosing algorithm to provide analgesia |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
STCB | Information on status: application discontinuation |
Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION |